HIV / AIDS in the News

Rapid increase of HIV contracted individuals in Hambantota - dailymirror.lk

 

‘De-siloing’ summit examines new possibilities for LGBTQ+ people living—and aging—with HIV - Windy City Times

 

HIV prevention therapy likely to become cheaper but accessibility concerns remain - The Times of India

 

Risk factors for diabetes in people with HIV - 2 Minute Medicine

 

Metabolic Risk Contributes to Diabetes Onset in People With HIV - HealthDay

 

HIVR4P 2024 Research Highlights: Reproductive Health While on PrEP and Signals to Guide HIV Vaccines and Cure - POZ

 

Can Women Living With HIV Safely Breastfeed? - Medpage Today

 

Q&A: Researchers discuss how PrEP medication can help lower HIV infections in women - Medical Xpress

 

Study Finds Telehealth Effective for HIV Patients - Rutgers University

 

Study of New Orleans Neighborhoods, Time to Viral Suppression, Shows Long Shadow of Redlining - Managed Healthcare Executive

 

Updating the Evidence on Drugs to Prevent Malaria in HIV-Positive Pregnant Women - Instituto de Salud Global de Barcelona

 

Walk to help AIDS Fund Philadelphia care for those with HIV, AIDS - NBC Philadelphia

 

HBCU Homecoming Turn The Spotlight On HIV Awareness And Prevention - Essence

 

How Women Can Reduce HIV Risk - Rutgers University

 

ViiV to triple annual supply of long-acting HIV PrEP for low- and middle-income countries - The Pharma Letter

 

GSK’s ViiV to expand supply of HIV drug in Africa - BioPharma Dive

 

CytoDyn Announces Abstract that Highlights Leronlimab’s - GlobeNewswire

 

Gilead Sciences (GILD) Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference - StreetInsider.com

 

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5 - Business Wire

 

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference - StockTitan

 

In long-acting HIV PrEP access showdown with Gilead, GSK moves to triple Apretude supply for certain countries - FiercePharma

 

3-Month Dapivirine Vaginal Ring for HIV Prevention Demonstrates Superior Drug Release Compared to 1-Month Ring - Population Council

 

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries - StockTitan

 

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries - Business Wire

 

Political Notes: SF mayoral contenders weigh in on backfilling federal HIV cuts - Bay Area Reporter, America's highest circulation LGBT newspaper

 

Opinion: Reproductive freedom should include conversations about PrEP for HIV prevention - Courier Journal

 

Flu Shot: Essential Protection for People with Chronic Conditions Like HIV - Parsippany Focus

 

Gilead Licenses Long-Acting HIV Prevention Drug to Generics Firms - MSN

 

Biden-Harris must ensure access to HIV prevention drugs - Washington Blade

 

Laredo Public Health hosts HIV testing and education event - Laredo Morning Times